<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders</h1>
    <p class="timestamp">Published: 2023-02-09 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The National Institute of Neurological Disorders and Stroke ("NINDS"), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to University College London Business, Ltd. ("UCLB"), incorporated in England and Wales under company registration number 02776963 whose registered office address is University College London, Gower Street, London WC1E 6BT, United Kingdom, for NINDS's rights to th...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2023-02772</p>
    <p><strong>Publication Date:</strong> 2023-02-09</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2023/02/09/2023-02772/prospective-grant-of-exclusive-patent-license-novel-therapeutics-for-the-treatment-of">https://www.federalregister.gov/documents/2023/02/09/2023-02772/prospective-grant-of-exclusive-patent-license-novel-therapeutics-for-the-treatment-of</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2023-02772</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
